ISB News

ISB Professor Sui Huang challenges the long-held belief that genetic mutations primarily drive cancer, offering a fresh perspective that could revolutionize how we think about and treat this complex disease.

Sui Huang challenges the prevailing view of cancer as purely genetic in a new essay published in PLOS Biology. Huang and colleagues suggest non-genetic factors and disrupted gene regulatory networks may play crucial roles in cancer development.

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.

Despite the aggressive nature of Non-Small Cell Lung Cancer (NSCLC), circulating tumor cells that lead to metastases often go undetected in the blood. ISB researchers in Dr. Wei Wei’s lab and their collaborators have developed a novel method to better detect these circulating cells.

CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.